Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other research firms have also weighed in on AQXP. ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Aquinox Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $22.00.
Hedge funds have recently made changes to their positions in the stock. University of Notre Dame DU Lac lifted its stake in Aquinox Pharmaceuticals by 11.1% in the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after acquiring an additional 19,066 shares during the period. Nexthera Capital LP purchased a new stake in Aquinox Pharmaceuticals in the second quarter worth $1,276,000. Vanguard Group Inc. lifted its stake in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after acquiring an additional 17,455 shares during the period. Sphera Funds Management LTD. lifted its stake in Aquinox Pharmaceuticals by 21.7% in the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after acquiring an additional 13,450 shares during the period. Finally, Northern Trust Corp lifted its stake in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after acquiring an additional 2,691 shares during the period. 96.25% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/12/aquinox-pharmaceuticals-aqxp-lowered-to-hold-at-zacks-investment-research.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.